Global bioreactor market to value over $16bn by 2027
A report indicates ongoing demand for COVID-19 vaccines and other biologics, as well as increasing investment will drive a 16.6 percent CAGR in the bioreactors market.
List view / Grid view
News
Personalised cancer vaccine safe and potentially beneficial to patients
Mount Sinai researchers reveal that, in a Phase I trial, their personalised cancer vaccines targeting cancer neoantigens showed some early signs of potential benefit.
Novel time-temperature indicator could help preserve mRNA vaccines
Researchers have developed a novel sensor, known as a time-temperature indicator, that could be used to monitor the storage conditions of mRNA vaccines.
Global Pharmacovigilance Observatory to aid pharma’s understanding of regulatory decisions
The observatory will collate drug safety data, analyses and decisions into a single source to help pharma identify regional differences in decision-making.
New group to tackle data governance and guide digital transformation in pharma
The Pistoia Alliance's Data Governance Community of Interest will develop best practices and advance digital transformation in the pharma/life sciences industry.
GSK Consumer Healthcare to incorporate paper bottles into its packaging
To meet its ambitious sustainability targets, GSK Consumer Healthcare has joined the Pulpex paper bottle consortium.
Deception is not necessary for the placebo effect, finds new study
The study found that patients with irritable bowel syndrome taking open-label placebo reported similar improvements to those taking double-blind placebo.
NIAID doses first patient with Moderna’s variant specific COVID-19 vaccine candidate
The trial will evaluate the safety and immunogenicity of the mRNA-1273.351 vaccine candidate in 200 healthy adult volunteers.
EC approves Cabometyx® and Opdivo® combination for advanced renal cell carcinoma
The combination was approved on Phase III trial results which show it doubled progression-free survival and reduced risk of death by 40 percent, compared to standard of care.
Celonic to produce 100 million doses of CureVac’s COVID-19 vaccine candidate
Production of CureVac’s CVnCoV vaccine will take place in Germany, with over 50 million doses expected to be produced in 2021.
Evrysdi™ approved for treatment of spinal muscular atrophy in Europe
The European Commission has granted marketing authorisation to Roche’s Evrysdi™ (risdiplam) as a treatment for spinal muscular atrophy in infants, children and adults.
First ever Award for Extraordinary Impact on Health bestowed on Moderna and Pfizer
While announcing 2021’s Top 10 Clinical Research Achievement Awards, the US Clinical Research Forum revealed that Pfizer and Moderna would be honoured for their COVID-19 vaccines.
What strains should be in this year’s seasonal influenza vaccines?
The European Medicines Agency has published its recommendations for 2021-2022 seasonal influenza vaccine composition.
Lenzilumab™ significantly improves survival in hospitalised COVID-19 patients
In a Phase III trial, adding Lenzilumab™ to steroid and remdesivir regimens improved the likelihood of survival without need for mechanical ventilation by 54 percent.
Immunotherapy vaccine shows promise in prostate cancer patients
The multi-targeted hAd5 immunotherapy vaccine was found to be safe and showed initial signs of efficacy in patients with advanced metastatic castration-resistant prostate cancer.
